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A B S T R A C TObjective: New therapies have attempted to improve on efﬁcacy out-
comes observed with docetaxel in patients with metastatic prostate
cancer (MPC) who are hormone-therapy refractory or castration-resistant.
In addition to the efﬁcacy, patient-reported outcomes (PROs) and toler-
ability need to be assessed to deﬁne treatment beneﬁt, as PROs measure
the patient’s subjective experience and can be correlated with hard
outcomes. The main objective of this study was to evaluate the survival
beneﬁt of new therapies and secondary efﬁcacy-related outcomes.
Assessment of the number of studies reporting PROs and tolerability
was also conducted. Methods: A predeﬁned search strategy was con-
ducted on major academic/governmental databases and conference
proceedings (2007–2011). Exclusion criteria were applied. Results: Of 77
studies identiﬁed, 26 (34%) evaluated survival as an end point; 14 (18%)
assessed PROs/tolerability. In chemotherapy-naive patients (no/minimal
symptoms), median overall survival (OS) was 26 months for sipuleucel-T.
In relapsed patients, the survival beneﬁt of cabazitaxel/abiraterone was
15 months and that of enzalutamide was 18 months. Denosumab
prolonged time to ﬁrst on-study skeletal-related event (20.7 monthssee front matter Copyright & 2013, International S
r Inc.
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n's current afﬁliation is with Medical Device Repodenosumab, 17.1 months zoledronic acid; P ¼ 0.0002, noninferiority;
P ¼ 0.008, superiority). Similar beneﬁt was documented with radium-223,
a new bone-targeted α-particle–emitting radiopharmaceutical. Radium-
223 also signiﬁcantly improved the OS (two-sided P ¼ 0.00185). Speciﬁc to
PROs, they were incorporated primarily as secondary end points, and
improvements in pain response (most commonly evaluated) were
variable among the agents. Last, the therapies were associated with
unique toxicities requiring careful consideration. Conclusions: The
results of this review demonstrate that the therapeutic landscape of
MPC has changed dramatically andmany therapies in MPC now show OS
improvements of about 4 months in the postdocetaxel setting.
Keywords: bone metastases, castration-resistant prostate cancer,
chemotherapy, hormonal therapy, overall survival, patient-reported
outcomes, prostate cancer, radiopharmaceuticals, skeletal-related
events.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Prostate cancer (PC) is the most common noncutaneous malig-
nancy in men in the United States, and rates are second only to
lung cancer as the cause of cancer-related mortality in men [1].
The American Cancer Society’s statistics for 2013 estimate that
about 238,590 new cases of PC will be diagnosed and 28,790 men
will die from this cancer [1]. The majority of cases of PC are
diagnosed in the early stages, with a 5-year survival rate of 100%
[2]. Patients with early-stage PC are managed with curative intent
by using deﬁnite primary treatment such as surgery and radia-
tion [3].
Unfortunately, as many as 10% to 50% of men who are initially
diagnosed with localized PC may experience disease progression,
most commonly to lymph nodes and bone [4]. Furthermore, at
initial diagnosis, 4% of the patients have metastatic PC (MPC), and
the 5-year survival rate for this population is poor at only 28.7%[2]. Therefore, treatment of locally advanced PC and MPC is far
more challenging, with androgen deprivation therapy (ADT)
being commonly used as the upfront treatment option [3,5]. In
clinical practice, patients with PC have two equally effective ADT
options: medical castration using a luteinizing hormone–releas-
ing hormone agonist or surgical castration using bilateral orchi-
ectomy [5]. Treatment with ADT reduces prostate-speciﬁc
antigen (PSA) and shrinks tumors because of initial dependence
on circulating androgens; however, response rates are not dura-
ble [6].
Consequently, patients who relapsed after primary ADT have
a progression-free survival (PFS) of only 18 to 24 months and
develop castration-resistant PC (CRPC) [7,8]. CRPC (the preferred
term because many men respond to additional androgen manip-
ulations) is deﬁned as sequential PSA rising and/or disease
progression despite castrate blood levels of testosterone (for-
merly referred to as androgen-independent, or hormone-ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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in CRPC, prolongation of survival has not been achieved histor-
ically in this patient population [11]. CRPC was considered nearly
incurable, and no therapeutic approach had shown a survival
advantage until 2004, when two large prospective trials con-
cluded that a docetaxel-based treatment prolonged median over-
all survival (OS) by around 3 months and docetaxel became the
standard ﬁrst-line regimen in symptomatic patients with CRPC
[12,13].
In the past few years, various chemotherapies, targeted
therapies, and immunotherapies have attempted to improve on
the efﬁcacy outcomes achieved with docetaxel in patients with
CRPC. Therapeutic research has expanded options in CRPC for
asymptomatic/minimally symptomatic and symptomatic popu-
lations and in patients failing docetaxel [5]. Over the last 2 years,
three systemic agents (sipuleucel-T, cabazitaxel, and abiraterone)
have been approved by the Food and Drug Administration (FDA)
after demonstrating OS improvements in patients with CRPC [5].
The latest investigational agents, including radium-223, an alpha
(α)-emitting radiopharmaceutical, and the recently FDA-approved
enzalutamide (MDV3100), an androgen receptor signaling inhib-
itor, have also reported survival advantage in patients with CRPC
[14,15]. Advances have also been made in the prevention and
treatment of bone metastases. This is of high importance
because the bone is the metastatic site in more than 80% of the
patients with CRPC [16,17]. In addition to zoledronic acid, deno-
sumab can be considered for the prevention of skeletal-related
events (SREs), and radium-223 and enzalutamide may become
valuable therapeutic options based on their positive SRE out-
comes [14,15].
Even though traditional efﬁcacy end points such as survival
remain the most reliable and preferred end points in cancer
decision making, patient-reported outcomes (PROs) have been
increasingly recognized as providing evidence of clinical beneﬁt
of oncology therapies [18]. PROs, including a patient’s quality of
life (QOL), physical functioning, or tumor-related symptoms, can
provide essential information on the overall burden of cancer and
the effectiveness of therapies [18]. PROs assess the patient’s
subjective experience and can be correlated with hard outcomes
(e.g., pain intensity and survival) [18]. The assessment of PROs is
particularly important in patients with metastases who experi-
ence various skeletal-related complications [19]. In addition to
PROs, tolerability of these agents needs to be assessed to fully
deﬁne treatment beneﬁt and make individualized treatment
decisions in the CRPC population.
The growing number of therapeutic options highlights a need
to systematically evaluate the role of new systemic therapies in
patients with MPC. The present investigation will assess in a
systematic manner the published evidence on efﬁcacy, PROs, and
tolerability of the emerging therapies in CRPC. The primary
objective of this systematic review was to evaluate the survival
beneﬁt of new systemic therapies. Secondary efﬁcacy outcomes
(time to progression [TTP], PSA response rate, time to PSA
progression, and time to ﬁrst on-study SRE) were also assessed.
In addition, the present investigation evaluated the number of
studies reporting PROs and tolerability of new systemic therapies
in CRPC.Methods
Literature Search
Initially, we conducted a systematic literature search on docu-
ments and articles published in the English language between
January 1, 2004, and April 30, 2011. The starting date for this
systematic review was selected to evaluate both off-label and on-label evidence for docetaxel (FDA approval of May 19, 2004). Next,
we performed a supplementary systematic literature search from
May 1, 2011, until June 30, 2012, focusing on comparative studies
for abiraterone, enzalutamide, and radium-223 to account for an
emergence of new data. We used the following databases to
identify relevant studies: MEDLINE (via PubMed), EMBASE, the
Cochrane Library, Agency for Healthcare Research and Quality
(AHRQ), Community of Science, research registries of Clinical-
Trials.gov and National Research Register, and citation lists of
published systematic reviews and health technology assess-
ments. We also searched abstracts presented from 2007 to 2012
at major oncology conferences, including the American Society of
Clinical Oncology (ASCO) and the European Society of Medical
Oncology (ESMO). Detailed information on our search strategy is
outlined in Table 1. Controlled clinical trials, retrospective cohort
studies, and literature reviews were included to ensure that this
systematic review was comprehensive in scope and reﬂective of a
dynamic PC space, especially as it relates to a changing treatment
paradigm. Studies in children, non-English language studies, case
reports/series, and studies with preliminary/incomplete results
were excluded.
Data Extraction and Evidence Rating
One reviewer used the titles and abstracts identiﬁed in the initial
literature search to identify potentially relevant publications, the
full-text versions of which were retrieved and evaluated by two
reviewers. Study characteristics, including design/sample size/
treatments, inclusion/exclusion criteria, and end points/results,
were extracted and summarized on a standardized form for the
included publications. Because the objective of the review was
qualitative in nature, retrieved publications were not scored on
the basis of predeﬁned quality criteria.
The eligible articles (single-agent and comparative studies)
were assigned a level of evidence as described by the AHRQ of the
US Department of Health and Human Services: level 1, evidence
from well-designed randomized, controlled trials; level 2, evi-
dence from well-designed, nonrandomized controlled trials; level
3, evidence from well-designed observational studies with con-
trols, including retrospective and case-control studies; and level 4,
observational studies without controls, including cohort studies
without controls and case series. In addition, a strength of
evidence (SOE) was determined, as described by a modiﬁed
version of the AHRQ, which includes the domains of bias,
consistency, and directness (the domain of precision was not
included in the rating): high, high conﬁdence that the evidence
reﬂects the true effect; moderate, moderate conﬁdence that the
evidence reﬂects the true effect; and low, low conﬁdence that the
evidence reﬂects the true effect. The SOE was assigned on the
basis of a point value for the three domains ranging from 1 to 3,
with more points given to studies with lowest bias, deﬁnite
consistency, and directness: high, 2 to 3 points; moderate, 1 to
less than 2 points; and low, 0 to less than 1 point. Literature
reviews have been excluded from this evidence assessment
because it was anticipated that their numbers would be small
and not allow conclusive ratings.Results
Study Disposition and Characteristics
Overall, 782 publications were identiﬁed through the database
search and the ASCO/ESMO abstracts in the primary literature
search. After removal of 282 duplicates, 500 publications
remained. Subsequently, only 93 publications were included in
this systematic literature review following evaluation by the
Table 1 – Methods and strategies used for the
primary systematic literature search.
Method Strategy
Databases MEDLINE (via PubMed), January 1, 2004–April 30,
2011; EMBASE, January 2004–April 2011;
Cochrane Library, January 2004–April 2011;
abstracts presented at therapeutic conferences
of ASCO and ESMO over 4 years (2007–2011);
research registries of ClinicalTrials.gov,
National Research Register; citation lists of
published systematic reviews and health
technology assessments (2004–2011); and
Internet sites of AHRQ, COS, and NICE.
Search
terms
MeSH Headings Speciﬁc Terms
Antineoplastic
agents
Mitoxantrone
Taxiods Docetaxel
Microtubule inhibitor Cabazitaxel
Autologous cellular
immunotherapy
Sipuleucel-T
Pregnenolone analog Abiraterone
Antibodies,
monoclonal
Denosumab
Protein kinase
inhibitors
Dasatinib,
Cabozantinib [XL184]
Lanthanoid series
elements
Strontium, Samarium
Bisphosphonates Zoledronic acid
Androgen receptor
agonist
Enzalutamide
[MDV3100]
Endothelin A
receptor
antagonist/
pyrrolidine
Zibotentan [ZD4054]
Quinoline/
angiogenesis
inhibitor
Tasquinimod
Synthetic vaccines rF-TRICOM vaccine
(PROSTVAC-VF)
Oligonucleotides,
antisense
OGX-011
Recombinant fusion
protein
VEGF Trap [AVE 0005]
Immunomodulator/
pipiridine
derivative
Lenalidomide
Non-steroidal
androgen
synthesis
inhibitor/lyase
inhibitor
TAK-700
LHRH agonist/
gonadorelin
derivative
Leuprolide, Goserelin,
Triptorelin, Histrelin
Antiandrogen Bicalutamide,
Flutamide,
Nilutamide
Adrenal androgen
inhibitors
Ketoconazole, Steroids
Estrogens Diethylstilbestrol
Table 1 – continued
Method Strategy
Other treatment
options
Salvage radical
prostatectomy,
radiation therapy,
antiandrogen
withdrawal
and
 PC (general), prostatic neoplasm, locally advanced PC, CRPC,
mCRPC, HRPC, bone metastases in HRPC, bone metastases,
skeletal metastases
 Survival, PFS, OS
Publication
inclusion
criteria
Publications that reported on survival, PROs, and
tolerability; study types: randomized clinical
trials (phase 2/3), systematic literature reviews,
meta-analyses, retrospective cohort studies,
noncomparative (if a rigid study design), QOL
Publication
exclusion
criteria
Non-English language, case reports or series,
unpublished research or studies available only
as abstracts (except from ASCO/ESMO
conferences), studies reporting preliminary or
incomplete results, articles evaluating surgical
or radiotherapy intervention in newly
diagnosed PC patients, pharmacokinetic/
pharmacodynamic studies, preclinical (animal)
studies, sample size o25 patients
AHRQ, Agency for Healthcare Research and Quality; ASCO, Amer-
ican Society of Clinical Oncology; CAS, Chemical Abstract Service;
COS, Community of Science; CRPC, castration-resistant prostate
cancer; ESMO, European Society of Medical Oncology; HRPC,
hormone-resistant prostate cancer; LHRH, luteinizing hormone-
releasing hormone; mCRPC, metastatic castration-resistant pros-
tate cancer; MeSH, Medical Subject Headings; NICE, National
Institute for Health and Clinical Excellence; OS, overall survival;
PC, prostate cancer; PFS, progression-free survival; PRO, patient-
reported outcome; QOL, quality of life.
 Corresponding CAS Registry number was included in search if
available.
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after 16 publications were excluded because of outcomes non-
relevant to the initial literature review scope upon further review
by the primary reviewer and the client, with an additional 49
publications excluded following evaluation by the secondary
reviewer.
The main reasons for exclusion were articles with nonrelevant
drug interventions, patient populations, disease states, publica-
tion types, assessment/scope, and study phase evaluated. Figure 1
shows the disposition of publications identiﬁed for the ﬁrst part of
this systematic literature review, along with the secondary search.
From the primary literature search, 30 full-text publications/
selected abstracts were included in the data extraction after
meeting the predeﬁned eligibility for survival, tolerability, and
PRO assessments from the primary literature search. A summary
of the included studies is provided in Table 2. Of those publica-
tions/abstracts, there were 21 single-agent or comparative stud-
ies and 9 literature reviews (only 2 were systematic literature
reviews). Speciﬁc to the single-agent or comparative studies,
there were 5 studies with a retrospective design and 16 studies
with a prospective design.
The secondary search of this literature review identiﬁed an
additional 30 publications through the database search and the
622 publications identified through database search
160 publications identified through ASCO/ESMO abstracts
500 publications remained after 282 duplicates removed
93 publications met eligibility 
after screening by primary 
reviewer
407 publications excluded due to non-
relevant drug intervention, disease 
condition, study population, publication 
type, study assessment/scope, or study 
phase evaluated  
77 publications met eligibility 
after screening by secondary 
reviewer
49 publications excluded due to non-
relevant outcomes evaluated, <25 
patients, non-English language, or 
abstract or publication unavailable upon 
retrieval 
PRIMARY SEARCH (04/2004–04/2011)
SECONDARY SEARCH (05/2011–06/2012)
9 publications identified through database search
21 publications identified through ASCO/ESMO 
abstracts
6 full-text articles/abstracts included in data extraction
36 publications identified through database search and 
ASCO/ESMO abstracts
24 publications excluded due to 
non-relevant drug intervention, 
disease condition, study population, 
publication type, study 
assessment/scope, or study phase 
evaluated  
16 publications were excluded due to 
outcomes non-relevant to the initial 
literature review scope upon further 
review by the primary reviewer and the 
client
30 full-text articles/abstracts included in data extraction
21 single-agent or comparative studies
9 literature reviews
Fig. 1 – Disposition of publications identiﬁed for this systematic literature review.
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24 publications were excluded following evaluation by the pri-
mary reviewer. The main reasons for exclusion were articles with
nonrelevant drug interventions, patient populations, disease
states, publication types, assessment/scope, and study phase
evaluated. At that point, 6 remaining publications from the
secondary search were combined with 30 publications from the
primary search for a ﬁnal total of 36 publications.
The majority of studies (67%; n ¼ 18) provided level 1 evidence,
7% (n ¼ 2) provided level 2 evidence, 22% (n ¼ 6) provided level 3
evidence, and 4% (n ¼ 1) provided level 4 evidence. The SOE for
the studies was distributed as follows: 52% (n ¼ 14) were high, 33%
(n ¼ 9) were moderate, and 15% (n ¼ 4) were low.Efﬁcacy Results
Study description
The detailed descriptions of efﬁcacy (focusing on OS), PROs, and
tolerability assessments from the pivotal studies in the treatment of
metastatic CRPC (mCRPC) identiﬁed during this analysis are further
outlined in the “Results” section with the corresponding summary
tables. In general, all the pivotal investigations were phase 3 random-
ized clinical trials and the majority of them enrolled chemotherapy-
naive or postdocetaxel patients with CRPCworldwide. Considering the
OS beneﬁt of recently approved and investigational systemic therapies
in CRPC and aligning them with recommendations from the National
Comprehensive Cancer Network guidelines, the results for the sys-
temic agents are presented for asymptomatic/minimally symptomatic
versus symptomatic patients and chemotherapy-naive versuspostdocetaxel patients. Next, data on the available bone-targeted
agents and their impact on delaying SREs in patients with bone
metastases are outlined. Last, PROs from the pivotal phase 3 studies
and the tolerability of systemic and targeted agents are discussed.
Metastatic chemotherapy-naive asymptomatic/minimally
symptomatic: Sipuleucel-T and abiraterone acetate
Traditionally, chemotherapy-naive patients were offered second-
line hormonal therapies if they were asymptomatic, and only ﬁt
symptomatic patients were considered for treatment with doce-
taxel [5]. In early 2010, the FDA approved sipuleucel-T, an
autologous cellular immunotherapy. Sipuleucel-T is targeted
against prostatic acid phosphatase (PAP), an antigen expressed
in most PCs, capable of causing an immune response [20].
Sipuleucel-T consists of the patient’s own antigen-presenting
cells that are incubated ex vivo with a recombinant fusion
protein (PAP2024) consisting of granulocyte macrophage colony-
stimulating factor and PAP [21]. Sipuleucel-T is indicated for the
treatment of patients with asymptomatic or minimally sympto-
matic mCRPC who are given two doses of sipuleucel-T adminis-
tered within 2 weeks of each other [22].
The pivotal study of sipuleucel-T that led to its approval was a
randomized, double-blind, placebo-controlled, multicenter phase
3 trial at 75 centers in the United States and Canada [23]. There
were 512 patients with asymptomatic or minimally symptomatic
mCRCP randomized 2:1 to receive sipuleucel-T [23]. The median
OS, which was the primary end point of this study, was 4.1
months longer in the sipuleucel-T arm (25.8 months) than in the
placebo arm (21.7 months). Patients in the sipuleucel-T group
Table 2 – Summaries of full-text articles and selected abstracts included in the data extraction of the
systematic literature search.
Study Study design Treatment Outcomes AHRQ
LOE
Modiﬁed
AHRQ
SOE†
Primary search
Single-agent studies (n ¼ 2)
[25] Retrospective analysis
of the RCT phase 1/2
(N ¼ 35)
D following abiraterone þ
dexamethasone
PSA decline of ≥50% was
seen in 9 (25.7%) patients
and PSA decline ≥30% was
seen in 13 (37.1%) patients.
Median time to PSA
progression was 4.6 mo
(95% CI 4.2–5.9) and
median OS was 12.5 mo
(95% CI 10.6–19.4)
4 Moderate
[17] RCT phase 2 (N ¼ 43) D þ samarium-153
(consolidation)
Median PSA-PFS was 6.4 mo
(95% CI 6–7), and clinical
PFS was 15 mo (95% CI 11–
29) in the overall patient
population. In patients
who received
consolidation regimen, 15
had no PSA progression at
7 mo
2 Moderate
Comparative studies (n ¼ 25)
Retrospective studies
[26] Retrospective analysis
(N ¼ 175)
“Standard” regimen (SR) D
vs. “adapted” regimen
(AR) D
In patients older than 75 y
considered ﬁt for SR, D has
similar efﬁcacy and safety
proﬁle as in younger
patients. Median OS was
15 mo (95% CI 12.8–17.1)
3 Moderate
[27] Retrospective analysis
(N ¼ 145)
D q3w þ P vs. M þ P For patients with mild or
moderate/pain, the risk of
death was 1.56 (95% CI
1.05–2.33; P ¼ 0.027) and
2.11 (95% CI 1.32–3.37)
times higher than for
patients with minimal or
no pain (P ¼ 0.002). The
median OS for
asymptomatic patients on
docetaxel was better (23.1
mo [95% CI 18.5–27.6])
than for symptomatic
patients (13.5 mo [95% CI
6.9–20.1])
3 Moderate
[28] Retrospective analysis
of the RCT phase 3
study (N ¼ 815)
See [13] 374/815 (46%) men had
substantial pain at
baseline (PPI ≥2 or AS ≥10);
of these, 345 (92%) had
substantial impairment of
QOL (FACT-P score ≤128).
Median OS for men with
minimal symptoms was
25.6 mo (95% CI 21.6–28.4)
vs. 17.1 mo (95% CI 16.2–
18.3) for more
symptomatic patients (P ¼
0.009)
3 High
[29] Retrospective analysis
of the RCT phase 3
study (N ¼ 232)
D q3w þ P - M þ P vs. D
weekly þ P - M þ P vs.
M þ P- D q3w or weekly
þ P
Median OS after crossover
was 10 mo regardless of
the sequence of regimens.
Median PSA PFS was 3.4
3 Moderate
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Table 2 – continued
Study Study design Treatment Outcomes AHRQ
LOE
Modiﬁed
AHRQ
SOE†
mo for M after D and 5.9
mo for D after M
[30] Exploratory analysis of
the RCT phase 3
(N ¼ 636)
ZA vs. placebo PSA increases correlated
with signiﬁcantly
increased risks of death
(RR 1.596), bone disease
progression (RR 1.159), and
ﬁrst SRE (RR 1.264; P o
0.0001 for all)
3 Moderate
Phase 1/2 studies
[31] RCT phase 1/2 studies
(N ¼ 292)
Radium-223 (phase 1/BCI-
04) Radium-223 vs. placebo
(BCI-02)
In the phase 2 study (BC1-
02), radium-223 increased
the median OS by 4.5 mo
vs. placebo (65 wk vs. 45
wk, respectively; HR 2.10; P
¼ 0.017). Less than 1% of
the patients had grade 4
hematologic AEs, 4.8% of
the patients had grade 3
anemia, and o3% of the
patients had grade 3
toxicity for platelets,
neutrophils, or white
blood cells
2 Moderate
[32] RCT phase 2 (N ¼ 44) Atrasentan þ ZA vs.
atrasentan
Changes in bone turnover
markers such as BAP did
not differ signiﬁcantly for
the atrasentan and
combination arms (P ¼
0.77). Changes in NTX
differed signiﬁcantly
between groups (P o
0.001)
1 Low
[16] RCT phase 2 (BCI-02)
(N ¼ 64)
Radium-223 vs. placebo Median relative change in
bone-ALP during
treatment was –65.6%
(95% CI –69.5 to –57.7) and
9.3% (95% CI 3.8–60.9) in
the radium-223 and
placebo groups,
respectively (P o 0.0001).
Median time to ﬁrst SRE
was signiﬁcantly longer
for radium-223 at 14 wk
vs. 11 wk in the placebo
arm (HR 1.75; CI 0.96–3.19;
P ¼ 0.065)
1 High
[33] RCT phase 2 (N ¼ 82) Custirsen [OGX-011] þ D þ
P vs. D þ P
A decline of ≥50% in PSA
occurred in 23 (58%)
patients treated with
OGX-011 (90% CI 43.3%–
70.8%) and 22 (54%)
patients treated with D
(90% CI 39.8%–67.1%)
1 Moderate
[34] RCT phase 2 studies
(N ¼ 186)
Radium-223 vs. placebo
(BCI-02) Radium-223
(BCI-04)
In BC1-02, radium-223
improved the OS by 4.5 mo
vs. placebo in patients
with CRPC and bone
metastases (65 wk vs. 46
wk; HR 2.10; P ¼ 0.017). In
3 Moderate
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 7 2 – 8 9 0 877
Table 2 – continued
Study Study design Treatment Outcomes AHRQ
LOE
Modiﬁed
AHRQ
SOE†
the BC1-04 study, the
median OS for patients
with and without ALP
normalization was 102
and 58 wk, respectively
(log-rank P ¼ 0.0086)
Phase 3 studies
[13] RCT phase 3 (N ¼ 1,006) D q3w þ P vs. D weekly þ P
vs. M þ P
Treatment with D q3w led to
superior survival (18.9 mo
vs. 16.5 mo) and improved
rates of response in terms
of pain, serum PSA level,
and QOL, as compared
with M plus P
1 High
[35] RCT phase 3 (N ¼ 950) Satraplatin þ P vs. placebo
þ P
Observed HR for progression
or death was 0.67 for
satraplatin vs. placebo
(95% CI 0.57–0.77; P o
0.001). No difference in OS
was seen between the
satraplatin and placebo
arms (HR 0.98; 96% CI
0.84–1.15; P ¼ 0.80)
1 High
[23] RCT phase 3 (N ¼ 512) Sipuleucel-T vs. placebo Median OS was 4.1 mo
longer with sipuleucel-T
(25.8 mo) than with
placebo (21.7 mo). The
sipuleucel-T group had a
relative reduction of 22%
in the risk of death as
compared with the
placebo group (HR 0.78;
95% CI 0.61–0.98; P ¼ 0.03)
1 High
[36] RCT phase 3 (N ¼ 1050) D þ P þ bevacizumab vs. D
þ P
Addition of bevacizumab to
D þ P did not improve OS
in men with mCRPC (22.6
mo vs. 21.5 mo; P ¼ 0.181)
1 High
[37] RCT phase 3 (N ¼ 755) Cabazitaxel vs. M Median OS for cabazitaxel
was 15.1 mo (95% CI 14.1–
16.3) and for mitoxantrone
was 12.7 mo (95% CI 11.6–
13.7). Cabazitaxel resulted
in a 30% reduction in the
RR of death (HR 0.70; 95%
CI 11.6–13.7; P o 0.0001)
1 High
[38] RCT phase 3 (N ¼ 1195) Abiraterone þ P vs. placebo
þ P
OS was longer in the
abiraterone acetate arm at
14.8 mo vs. the placebo
arm at 10.9 mo (HR 0.65;
95% CI 0.54–0.77; P o
0.001) in patients with
mCRPC
postchemotherapy
1 High
[39] RCT phase 3 (N ¼ 1904) Denosumab vs. ZA Median time to ﬁrst on-
study SRE was 20.7 mo for
denosumab (95% CI 18.8–
24.9) vs. 17.1 mo for ZA
(95% CI 15.0–19.4) (HR 0.82,
95% CI 0.71–0.95; P ¼
0.0002 for noninferiority; P
¼ 0.008 for superiority)
1 High
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Table 2 – continued
Study Study design Treatment Outcomes AHRQ
LOE
Modiﬁed
AHRQ
SOE†
[40] RCT phase 3 (N ¼ 592) D þ P þ risendronate vs. D
þ P
Addition of risedronate to D
þ P did not improve OS in
men with mCRPC (19.7 mo
vs. 18 mo; P ¼ 0.06)
1 High
[41] See [37] See [37] Rates of disease control were
higher in patients treated
with cabazitaxel (n ¼ 201)
than in the M (n ¼ 204)
group (61.7% vs. 47.5%; P ¼
0.004). Changes in pain
intensity and analgesic
medication use were
similar between the two
arms
1 Low
Secondary search
Phase 3 studies
[42] RTC phase 3 study
(N ¼ 1195)
Abiraterone þ P vs. placebo
þ P
In addition to the OS beneﬁt,
abiraterone-treated
patients experienced
delay in fatigue
progression and patient-
reported fatigue outcomes
and scores were more
rapidly improved with
abiraterone
1 Low
[43] RCT phase 3 study
(N ¼ 1195)
Abiraterone þ P vs. placebo
þ P
Abiraterone was associated
with durable pain
responses at the long-
term analysis and delay in
pain progression with
palliation rate of 45% in
the abiraterone arm vs.
28% in the placebo arm (P
¼ 0.0005)
1 Low
[15] RCT phase 3 study
(N ¼ 1199)
Enzalutamide vs. placebo Enzalutamide signiﬁcantly
prolonged the OS
compared with placebo in
patients with mCRPC (HR
0.631; 95% CI 0.529–0.752; P
o 0.0001). The median OS
was 18.4 mo in the
enzalutamide-treated
patients vs. 13.6 mo in the
placebo-treated patients
1 High
[14] RCT phase 3 (N ¼ 921) Radium-223 vs. placebo Radium-223 signiﬁcantly
improved the OS in CRPC
patients with bone
metastases (HR 0.695; 95%
CI 0.581–0.832; P ¼
0.00007). The median OS
was 14.9 mo for radium-
223 and 11.3 mo for
placebo
1 High
[44] RCT phase 3 (N ¼ 1088) Abiraterone þ P vs. placebo
þ P
Abiraterone showed
improvement in rPFS in
chemotherapy-naive
patients (HR 0.43; 95% CI
0.35–0.52; P o 0.0001).
There was a strong trend
for OS beneﬁt (27.2 mo for
1 High
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Study Study design Treatment Outcomes AHRQ
LOE
Modiﬁed
AHRQ
SOE†
placebo; not yet reached
for abiraterone; P ¼ 0.0097)
[45] RTC phase 3 study (N ¼
921)
Radium-223 vs. placebo Radium-233 signiﬁcantly
delayed both the time to
the ﬁrst SRE and SRE
components (spinal cord
compression) as well as
the time to ECOG PS
deterioration (HR 0.62; 95%
CI 0.46–0.85; P ¼ 0.003)
1 High
Literature reviews (n ¼ 9)
Study Summary
[46] Review outlined individualized approach for the use of radiotherapy in patients with mCRPC
[47] Review summarized the clinical development program for alpharadin, α-particle–emitting pharmaceutical for the treatment of
patients with cancer and bone metastases
[48] This review focused on experimental therapeutics for advanced PC, including signal transduction pathway inhibitors, growth
factors and growth factor receptor inhibitors, cell survival and tumor angiogenesis pathways, immunotherapy, and gene
therapies
[49] This systematic review evaluated clinical trials with PROs in patients with mCRPC treated with cytotoxic chemotherapy and
compared their results by traditional medical and PROs assessment
[50] Review discussed advances in bone-targeted therapies such as ZA and denosumab in the treatment and prevention of bone
complications in PC
[51] This systematic review assessed evidence for improved survival beneﬁt from RCTs with second-line treatment options in
patients with mCRPC previously treated with D
[52] Review outlined the new molecular targets in bone metastases management, with the primary focus on denosumab
[53] Review discussed the use of external beam radiation and β-emitting isotopes, and new α in palliation of bone metastases and
for radiation and treatment of painful bone metastases with a focus on PC
[54] Review summarized novel anticancer drugs and treatment pathways for CRPC, including discussion on cabazitaxel,
sipuleucel-T, abiraterone, enzalutamide, radium-223, and other agents that demonstrated early signs of activity in CRPC
AE, adverse event; AHRQ, Agency for Healthcare Research and Quality; ALP, alkaline phosphatase; AR, “adapted” regimen; BAP, bone alkaline
phosphatase; CI, conﬁdence interval; CRPC, castration-resistant prostate cancer; D, docetaxel; ECOG, Eastern Cooperative Oncology Group; HR,
hazard ratio; FACT-P, Functional Assessment of Cancer Therapy-Prostate; LOE, level of evidence; M, mitoxantrone; mCRPC, metastatic
castration-resistant prostate cancer; NTX, N-telopeptide; OS, overall survival; P, prednisone; PC, prostate cancer; PFS, progression-free survival;
PPI, Present Pain Intensity; PRO, patient-reported outcome; PS, performance status; PSA, prostate-speciﬁc antigen; q3w, every 3 wk; QALY,
quality-adjusted life-year; QOL, quality of life; RCT, randomized controlled trial; rPFS, radiographic PFS; RR, relative risk; SOE, strength of
evidence; SR, “standard” regimen; SRE, skeletal-related event; ZA, zoledronic acid.
 LOE as described by the AHRQ of the US Department of Health and Human Services: level 1, evidence from well-designed RCTs; level 2,
evidence from well-designed, non-RCTs; level 3, evidence from well-designed observational studies with controls, including retrospective
and case-control studies; and level 4, observational studies without controls, including cohort studies without controls and case series.
† SOE as described by a modiﬁed version of the AHRQ that includes the domains of bias, consistency, and directness (the domain of precision
was not included in the rating): high, high conﬁdence that the evidence reﬂects the true effect; moderate, moderate conﬁdence that the
evidence reﬂects the true effect; low, low conﬁdence that the evidence reﬂects the true effect. The SOE was assigned on the basis of a point
value for the three domains ranging from 1 to 3, with more points given to studies with lowest bias, deﬁnite consistency, and directness:
high, 2–3 points; moderate, 1–o2 points; and low, 0–o1 point.
This rating system assigned a point value to each level of evidence ranging from 1 to 5, with more points given to studies with higher levels
of evidence: level I, 5 points; level II-1, 4 points; level II-2, 3 points; level II-3, 2 points; and level III, 1 point.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 7 2 – 8 9 0880experienced a relative reduction of 22% in the risk of death than
did those in the placebo group (hazard ratio [HR] 0.78; 95%
conﬁdence interval [CI] 0.61–0.98; P ¼ 0.03). The estimated
probability of survival at 3 years was 31.7% in the sipuleucel-T
arm and 23.0% in the placebo arm. A similar survival advantage
was demonstrated by an earlier phase 3 study, although the
primary end point of TTP was not achieved [24].
A second therapeutic option, abiraterone (hormonal therapy),
has recently been approved for use in chemotherapy-naive
patients with CRPC, expanding its earlier FDA indication for the
management of postchemotherapy patients. Abiraterone acetate
is converted in vivo to abiraterone, an inhibitor of microsomalenzyme (cytochrome P17) expressed in testicular, adrenal, and
prostatic tumor tissues essential to androgen synthesis [55].
Evaluation of abiraterone compared with placebo with concurrent
prednisone in both arms (COU 302) in prechemotherapy popula-
tion resulted in improvement of radiographic PFS (co-primary
end point) and a strong trend for OS beneﬁt [44]. Median radio-
graphic PFS was 16.5 months in the abiraterone arm and 8.3
months in the placebo arm (HR 0.43; 95% CI 0.35–0.52; P o 0.001).
Median OS was not yet reached in patients treated with abirater-
one and was 27.2 months in patients treated with placebo (HR
0.75; 95% CI 0.61–0.93; P ¼ 0.01). Considering the recent FDA
approval, abiraterone has a potential to become a valuable option
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 7 2 – 8 9 0 881in chemotherapy-naive patients with asymptomatic/minimally
symptomatic disease.
Metastatic chemotherapy-naive symptomatic: Docetaxel
As previously stated, docetaxel is the mainstay of therapy for
chemotherapy-naive patients with symptomatic mCRPC. The
investigation of docetaxel as ﬁrst-line chemotherapy dates back
to the 1996 FDA approval of the combination of mitoxantrone and
prednisone (the comparator arm), demonstrating palliative ben-
eﬁt of this combination, but no survival beneﬁt [56,57]. Docetaxel
is indicated in combination with continuous prednisone for the
treatment of patients with androgen-independent MPC [58]. The
recommended dose of docetaxel is 75 mg/m2 every 3 weeks as a
1-hour intravenous infusion [58].
The TAX327 phase 3 clinical trial enrolled 1006 men with
chemotherapy-naive mCRPC and randomly assigned them to
weekly docetaxel for 5 out of 6 weeks or mitoxantrone or
docetaxel every 3 weeks [57]. Compared with the men in the
mitoxantrone group (OS 16.5 months), patients in the every-3-
weeks docetaxel group had an increased OS of 18.9 months, with
an HR for death of 0.76 (95% CI 0.62–0.94; P ¼ 0.009) [57]. Similar
beneﬁt in OS was observed in the second trial comparing
docetaxel in combination with estamustine with mitoxantrone
[12]. The updated extended follow-up survival data from this
study showed an absolute median OS of 19.2 months (95% CI
17.5–21.3 months) in the every-3-weeks docetaxel arm versus 16.3
months (95% CI 14.3–17.9 months) in the mitoxantrone arm [59].
Metastatic symptomatic postdocetaxel: Cabazitaxel, abiraterone
acetate, enzalutamide, and radium-223
The management of patients with disease progression during or
following docetaxel-based chemotherapy had been a key chal-
lenge for oncologists until the approvals of cabazitaxel and
abiraterone. Cabazitaxel is a taxane that exhibits antitumor
activity in preclinical models resistant to paclitaxel and docetaxel
[60,61]. In contrast to other taxanes (paclitaxel and docetaxel),
cabazitaxel appears to have low afﬁnity for P-glycoprotein, which
may contribute to the lack of apparent cross-resistance of
cabazitaxel [62]. Cabazitaxel is indicated in combination with
prednisone for the treatment of patients with CRPC who pre-
viously had failed a docetaxel-based regimen [63]. The FDA-
approved dose of cabazitaxel is 25 mg/m2 administered intra-
venously every 3 weeks over 1 hour in combination with oral
prednisone given throughout cabazitaxel treatment [63].
Cabazitaxel is the ﬁrst drug to improve OS in patients with
mCRPC who developed disease progression during or after
docetaxel-based chemotherapy [37]. The cabazitaxel indication
was supported by data from the open-label phase 3 trial (TROPIC)
that enrolled 755 patients with docetaxel-treated mCRPC and
randomized them to prednisone 10 mg once a day and either
mitoxantrone or cabazitaxel [37]. The median OS was 15.1
months (95% CI 14.1–16.3) in the cabazitaxel group and 12.7
months (95% CI 11.6–13.7) in the mitoxantrone group. The HR
for death of men treated with cabazitaxel compared with those
taking mitoxantrone was 0.70 (95% CI 0.59–0.83; P o 0.0001).
As previously stated, abiraterone in combination with predni-
sone is indicated for the treatment of patients with mCRPC who
have received prior chemotherapy containing docetaxel [64]. The
recommended dose of abiraterone is 1000 mg administered orally
once daily on an empty stomach in combination with prednisone
5 mg administered orally twice daily [64]. The FDA approval of
abiraterone for second-line therapy in CRPC was based on the
phase 3 study (COU 301). This international study was placebo-
controlled and enrolled 1158 patients with mCRPC who previ-
ously failed docetaxel [38]. At the median follow-up of 12.8
months, OS was longer in the abiraterone arm at 14.8 monthsthan in the placebo arm at 10.9 months (HR 0.65; 95% CI 0.54–
0.77; Po 0.001), leading to data unblinding (exceeded preplanned
criteria) and study termination. At the time of the preplanned
interim analysis, there was a 35.4% reduction in the risk of death
in the abiraterone-treated patients than in placebo-treated
patients (HR 0.65; 95% CI 0.54–0.77; P o 0.001).
Moving on to the latest investigational agents, enzalutamide
is the ﬁrst oral androgen receptor signaling inhibitor, recently
approved by the FDA for docetaxel-pretreated CRPC, that was
investigated in the randomized, double-blind, placebo-controlled,
multinational phase 3 study (AFFIRM) in patients who previously
have failed docetaxel [15]. Based on a planned interim analysis at
520 death events from 1199 patients, the study was unblinded,
allowing for patient crossover to the MDV3100 arm after a
signiﬁcant OS beneﬁt was documented (HR 0.631; 95% CI 0.529–
0.752; P o 0.0001) [15]. The median OS was 18.4 months for
MDV3100-treated men compared with 13.6 months for placebo-
treated men, offering an additional therapeutic option for
patients with CRPC [15].Bone-targeted therapies in patients with bone metastases
The development of bone metastases in CRPC is associated with
high morbidity, including pain, pathologic fractures, spinal com-
pression, and bone marrow suppression, and they also contribute
to mortality in patients with CRPC [16]. Suspending bone resorp-
tion by inhibiting the activity of osteoclasts has been shown to be
beneﬁcial for men with PC by decreasing the incidence of SREs in
patients with mCRPC; however, historically, bone-targeted thera-
pies have not improved survival [50]. Inhibition of osteoclasts can
be achieved with bisphosphonates or the monoclonal antibody
denosumab [50]. Zoledronic acid is a bisphosphonate indicated in
combination with standard chemotherapy for the treatment of
patients with multiple myeloma and patients with bone meta-
stases from solid tumors, including PC [65]. Speciﬁc to PC,
patients considered for treatment with zoledronic acid should
have progressed after treatment with at least one hormonal
therapy [65]. The recommended dose of zoledronic acid (creati-
nine clearance 460 mL/min) in patients with multiple myeloma
and bone metastases from solid tumors is 4 mg infused over at
least 15 minutes every 3 to 4 weeks [65].
Zoledronic acid was approved by the FDA to treat men with
CRPC and bone metastases based on results from a prospective,
randomized trial comparing it to placebo [66]. The zoledronic acid
arm had fewer SREs than did the placebo arm (33.2% vs. 44.2%;
P ¼ 0.021) and a longer median time to ﬁrst SRE (488 days vs. 321
days; P ¼ 0.009) [66]. Survival difference between the two arms
was not statistically different (546 days vs. 464 days; P ¼ 0.091).
Even though PC bone metastases are predominantly osteo-
blastic in appearance, leading to excess bone formation, the
compensatory activation of osteolytic response is mediated by
osteoclasts [67]. Denosumab is a human monoclonal antibody
that binds to human receptor activator of nuclear factor-κβ
ligand, which is essential for the formation, function, and
survival of osteoclasts [10]. Denosumab prevents receptor activa-
tor of nuclear factor kappa-B ligand from activating its receptor,
receptor activator of nuclear factor kappa-B, on the surface of
osteoclasts and their precursors [20]. Denosumab is indicated for
the prevention of SREs in patients with bone metastases from
solid tumors [68]. The FDA-approved dose of denosumab is 120
mg given subcutaneously in the upper arm, upper thigh, or
abdomen every 4 weeks [68].
Three randomized, double-blind, phase 3 studies provided
evidence for the FDA approval of denosumab for the prevention
of SREs in patients with bone metastases from solid tumors,
including PC [39,69,70]. One of the studies compared denosumab
with zoledronic acid in 1904 patients with mCRPC [39].
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delaying the time to ﬁrst on-study SRE, with an HR of 0.82 (95% CI
0.71–0.95; P ¼ 0.0002) for noninferiority and 0.008 for superiority
[39]. The median time to ﬁrst on-study SREs improvement was
20.7 months for denosumab compared with 17.1 months for
zoledronic acid [39]. There was no statistically signiﬁcant differ-
ence between the two treatment arms for OS and TTP [39].
In addition to bisphosphonates, radiopharmaceutical agents
have been used for men with CRPC. Historically, however, these
agents have primarily been used for palliation beneﬁt, with no
impact on OS. The two radiopharmaceutical agents, strontium-89
and samarium-153, are beta (β)-emitting agents that have been
shown to improve pain from osteoblastic bone metastases in
CRPC. Unfortunately, both can cause myelosuppression, limiting
their use in patients with compromised bone marrow reserves,
and may prevent the future administration of chemotherapy. To
overcome this safety concern and subsequently increase the use
of radiopharmaceuticals, novel agents have been in development
for mCRPC. Radium-223, a promising new α-emitting radiophar-
maceutical, targets bone metastases with high-energy, short-
range irradiation. This characteristic mechanism spares bone
marrow because of lower penetration to surrounding tissues
and limits toxic effects compared with traditional β-emitting
radiopharmaceuticals [16].
Radium-223 was investigated in a phase 3, double-blind,
randomized, multinational study (ALSYMPCA) that compared
radium-223 plus best standard of care versus placebo plus best
standard of care in patients with bone metastases in CRPC.
Following an updated analysis (prior to placebo patients crossing
over to radium-223), OS (the primary end point) was signiﬁcantly
increased in the radium-223 arm (HR 0.695; P ¼ 0.00007); the
median OS was 14.9 months for patients in the radium-223 arm
and 11.3 months for those receiving placebo [14]. Survival beneﬁt
was in favor of radium-223 across multiple patient subgroups,
including prior docetaxel use and bisphosphonate use.
SREs and SRE components such as spinal cord compression
were also lower in the radium-223 group versus the placebo group,
and time to ﬁrst SRE was signiﬁcantly delayed (median time to SRE
12.2 months vs. 6.7 months, respectively; P o 0.0001; HR 0.64; 95%
CI 0.52–0.78) [14]. Based on these positive data leading to the FDA
approval of radium-223 on May 15, 2013, radium-223 will most
likely emerge as an important therapeutic option for patients with
CRPC. It is important to point out that in addition to radium-223,
enzalutamide has been associated with meaningful SRE out-
comes, and both agents will most likely play a central role in
the management of patients with CRCP and bone metastases [15].
Detailed efﬁcacy data from pivotal phase 3 studies for bone-
targeted therapies with survival beneﬁt in CRPC are included in
Table 3.
Patient-Reported Outcomes
Our literature review found that the impact of systemic therapies
(docetaxel, cabazitaxel, abiraterone, enzalutamide, and radium-
223) on PROs has been studied, but the PRO results are often
published after and separately from the clinical trial primary end
points. The study of zoledronic acid was the only study that
included detailed PRO results concurrently when reporting the
efﬁcacy outcomes. Based on the study end points described in the
published articles for denosumab and sipuleucel-T, the PROs
were either not included in the assessment or are yet to be
reported for these two agents.
Considering available data for systemic agents such as doce-
taxel, cabazitaxel, and abiraterone—because the most common
symptom of bone metastases from PC is pain—it is not surprising
that the most commonly reported PRO was pain measured by
using the Present Pain Intensity (PPI) instrument [71] or the BriefPain Inventory short form (BPI-SF). PPI is a verbal scale ranging
from 0 to 5, and higher numbers correlate with more pain. A
clinically meaningful change on the PPI has not been established.
The BPI-SF contains items rated from 0 (no pain) to 10 (pain as bad
as can be imagined) and measures the intensity of cancer pain
and interference of pain in a patient’s life [72,73]. A change of 2 to
3 points or 30% equates to a clinically meaningful improvement in
pain [74]. QOL was the second most common PRO assessed by
using the Functional Assessment of Cancer Therapy Prostate
Cancer (FACT-P) instrument [75,76]. The FACT-P is composed of
22 general questions about physical, social, emotional, and func-
tional well-being and 17 prostate-speciﬁc questions, contributing
to a maximum score of 156 points. Prostate-speciﬁc questions
such as fatigue, bone pain, overall pain, pain-limiting perform-
ance, weight loss, ability to enjoy life, and difﬁculty urinating are
considered the most important symptom targets. A 6- to 10-point
change in FACT-P is a clinically meaningful change [77].
The TAX 327 study utilized a 16-point change in the FACT-P
score to determine a QOL response, 6 points higher than the
documented minimal clinical change difference. Improvement in
QOL response was demonstrated with docetaxel in both the
weekly (23%, 95% CI 18–28; P ¼ 0.005) and the every-3-week
docetaxel (22%, 95% CI 17–27; P ¼ 0.009) regimen when compared
with mitoxantrone (13%, 95% CI 9– 18) [13,28]. Reductions in bone
pain, measured by the PPI, were also documented in both
docetaxel arms but were statistically signiﬁcant only in the
every-3-week docetaxel arm (35%, 95% CI 27–43; P ¼ 0.01) when
compared with the mitoxantrone arm (22%, 95% CI 16– 29); a pain
response based on the PPI was deﬁned as an increase of 2 or more
points from baseline on the PPI without an increase in the
analgesic score or a decrease of 50% or more in the analgesic
score without an increase in the PPI score maintained for 3 or
more weeks (as noted, a clinically meaningful change has not
been deﬁned) [28]. Higher improvement in QOL and pain
response was also demonstrated in patients who crossed over
from the every-3-week docetaxel arm than in those in the
mitoxantrone arm [28]. The PPI response as previously deﬁned
was 43% for the every-3-week docetaxel arm versus 29% for the
mitoxantrone arm (no P value provided; a clinically meaningful
difference has not been deﬁned). The patient subgroup with no
pain or pain at baseline showed a median OS of 21.3 months (HR
0.73) and 14.2 months (HR 0.85), respectively [59].
The zoledronic acid study assessed the PROs of pain and QOL.
The results of the BPI-SF analysis showed a statistically signiﬁ-
cant but not a clinically meaningful difference (i.e., 2−3 points) for
the zoledronic acid 8/4 mg group versus placebo; a change of 0.43
(95% CI 0.29–0.87) from baseline was noted for the zoledronic 8/4
mg group versus 0.88 (95% CI 0.61–1.15) for placebo (P ¼ 0.026)
[66]. Sufﬁcient data on QOL were not provided.
When evaluating initial PRO data from the pivotal study of
abiraterone administered postchemotherapy, the rate of palliation
among patients with a baseline pain score of 4 or more and at
least one postbaseline pain score favored patients on abiraterone
compared with placebo (44% vs. 27%, P ¼ 0.002) [38]. Long-term
results reafﬁrmed that abiraterone maintained durable pain
responses and delayed pain progression with a palliation rate of
45% in the abiraterone arm versus 28% in the placebo arm (P ¼
0.0005) [43]. Patients with a baseline BPI level of less than 4 (no
clinically signiﬁcant pain) had an OS of 16.2 months and 13.0
months for abiraterone compared with placebo, respectively (HR
0.64; 95% CI 0.50–0.82); patients with a baseline BPI of 4 or more
(clinically signiﬁcant pain) had an OS of 12.6 months and 8.9
months, respectively (HR 0.68; 95% CI 0.53–0.85) [38]. Subsequent
reporting on fatigue outcomes showed clinically meaningful
improvement/reduction in this PRO in the abiraterone arm, as
well as delay in the TTP in fatigue intensity and interference; a
change of 1.25 or more points on the fatigue interference scores
Table 3 – Efﬁcacy outcomes of systemic and bone-targeted therapies from CRPC from pivotal phase 3 studies.
Efﬁcacy end
point
Prevention of SRE First-line therapy
asymptomatic/ minimally
symptomatic
First-line
therapy
symptomatic
Second-line postdocetaxel symptomatic
Zoledronic
acid
Denosumab Sipuleucel-
T
Abiraterone
acetate
Docetaxel Abiraterone
acetate
Enzalutamide Cabazitaxel Radium-
223
Comparator Placebo Zoledronic
acid
Placebo Placebo Mitoxantrone Placebo Placebo Mitoxantrone Placebo
Median OS
(mo),
18.2 19.4 25.8 Not reached 18.9/17.4 14.8 18.4 15.1 14.9
NR 1.03 0.775 0.75 0.76 0.65 0.70 0.695
HR (P value) (0.091) (0.65) (0.032) (0.001) (0.009) (o0.001) (o0.0001) (0.00007)
Median TTP
(mo)
3.0 8.4 3.7 16.5 (rPFS) – 10.2 8.3 (PFS) 2.8 (PFS) –
PSA response
rate (%)
– – – 62 45/48 38 54 39 –
Median time to
PSA
– – – 11.1 7.7/8.2 5.6 8.3 6.4 NR
progression, 0.49 0.58 0.248 0.75 0.643
HR (P value) (o0.001) (o0.001) (o0.0001) (0.001) (o0.00001)
Median time to
ﬁrst on-study
16.3 20.7 – – – – 16.7 – 12.2
SRE (mo), NR 0.82 0.621 0.64
HR (P value) (0.009) (0.008 for
superiority;
(o0.0001) (o0.0001)
0.0002 for
noninferiority)
Trial [66] [39] [23] [44] [57] [38] [15] [37] [14]
HR, hazard ratio; NR, not reported; OS, overall survival; PSA, prostate-speciﬁc antigen; SRE, skeletal-related event; rPFS, radiographic progression- free survival; TTP, time to progression.
 Docetaxel was given as two schedules (every 3 wk and weekly).
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 7 2 – 8 9 0884and 2 or more points on the fatigue intensity scores represented a
clinically meaningful change. Study results showed that 55%
versus 38% of the patients receiving abiraterone versus placebo,
respectively, experienced improvement in fatigue interference and
57% versus 40%, respectively, experienced improvement in fatigue
intensity (P o 0.01 for both scales); close to half of the patients in
each group had clinically signiﬁcant fatigue intensity (deﬁned as a
score of ≥5 points) at baseline [42,78]. Similarly, in chemotherapy-
naive patients, the number of PROs, including the time to opiate
use (HR 0.69; 95% CI 0.57–0.83; P ¼ 0.0001) and the time to Eastern
Cooperative Oncology Group Performance Status (PS) deterioration
(HR 0.82; 95% CI 0.71–0.94; P ¼ 0.0053), favored the abiraterone arm
[44]. The authors concluded that abiraterone demonstrated clin-
ically meaningful effects on all secondary end points [44].
Pain response rates, as measured by the PPI and deﬁned per
the docetaxel study, were similar in the cabazitaxel and mitox-
antrone arms (9.2%, 95% CI 4.9%–13.5% vs. 7.7%, 95% CI 2.7%–
11.8%; P ¼ 0.63) (as noted, clinically meaningful change on the PPI
has not been deﬁned) [37]. Also, reductions or increases in pain
were comparable in both treatment arms [37]. PS remained stable
and similar in most men in each group during treatment (79% in
the cabazitaxel arm vs. 78% in the mitoxantrone arm), as were
the rates of PS worsening and improving [41].
Speciﬁc to enzalutamide, QOL responses by FACT-P were
superior across all domains in 43% of enzalutamide-treated
patients and 18% of placebo-treated patients (P o 0.0001) [15].
The actual point decrease on the scale was not provided nor was
the deﬁnition of FACT-P response; therefore, no conclusion about
the clinical meaningfulness of these data can be derived. Pain
response data are not yet available for enzalutamide. No data on
QOL outcomes are yet available for radium-223; however,
radium-223 has been shown to signiﬁcantly delay the time to
Eastern Cooperative Oncology Group PS deterioration (HR 0.62;
95% CI 0.46–0.85; P ¼ 0.003) [45].
Overall, most studies included multiple PRO parameters. In all
the studies, the primary end point was survival (systemic
therapies) or SREs (bone-targeted agents), and the PROs were
incorporated as the secondary end points. All studies of systemic
agents, except for cabazitaxel, showed positive correlation
between prolonged survival and PROs. Despite the magnitude of
change in QOL and durable pain response parameters in these
studies, interpretation of a clinically meaningful difference was
not routinely performed. Our post hoc assessment of clinically
meaningful difference indicates that docetaxel and enzalutamide
have documented improvement in PROs based on the FACT-P.
Improvements in pain response were observed for docetaxel
based on the PPI; however, a clinically meaningful difference
for this scale has not been established. PRO data using the BPI
and fatigue scales demonstrated clinically meaningful change for
abiraterone. Other studies either did not evaluate or did not
report FACT-P, PPI, or BPI data; as such, analysis and interpreta-
tion of these QOL and pain PRO data are limited. Last, even
though PS, a clinician-rated component of QOL assessment, is not
considered to be a PRO, it is important to point out that in many
cases, a minimum score was used for eligibility. Detailed PRO
data from pivotal phase 3 studies for new systemic and bone-
targeted therapies in CRPC are included in Table 4.Tolerability
Approved and emerging PC therapies offer considerable palliative
and survival beneﬁts to men with CRPC. Each of these agents,
however, is associated with distinctive toxicities, some poten-
tially incapacitating or life-threatening, that must be monitored
carefully and managed appropriately to provide patients with
CRPC the optimal level of care.Nearly one-third of the patients treated with docetaxel expe-
rienced grade 3/4 neutropenia, with febrile neutropenia occurring
in only 3% of the patients [13]. Docetaxel hypersensitivity reac-
tion, which is rare but can be life-threatening, was not reported in
the TAX327 trial but has been documented in clinical practice
[13,62]. Fluid retention is a characteristic adverse event (AE) of
docetaxel (particularly with higher cumulative doses) that can be
minimized or eliminated with steroid premedication in the
majority of patients [62]. Because of concerns about neutropenic
complications, severe hypersensitivity, or severe ﬂuid retention,
however, docetaxel has a black-box warning for these AEs. Also,
patients with elevated bilirubin and/or liver functions tests are at
an increased risk for docetaxel-related liver toxicities. Last,
sensory neuropathy that has a potential to negatively impact a
patient’s QOL, because of its irreversible nature in some patients,
occurred in 30% of the patients treated with docetaxel [13].
Many patients receiving docetaxel either suspend therapy
because of acute or cumulative toxicity or develop disease pro-
gression, and at that time can be considered for sipuleucel-T,
cabazitaxel, or abiraterone. Themost common AEs with sipuleucel-
T within 1 day of infusion were chills, fever, fatigue, nausea, and
headache [23]. Mild to moderate acute infusion-related reactions
were frequently reported in patients receiving sipuleucel-T (95%);
however, events of grade 3 or greater were rare (4%) [22].
The AE proﬁle of cabazitaxel was similar to that seen with
other taxanes. The most common grade 3 or greater AE with
cabazitaxel included neutropenia (82%) and diarrhea (6%) [37]. In
addition, 8% of the patients in the cabazitaxel group had febrile
neutropenia; because neutropenic deaths have been reported,
cabazitaxel carries a black-box warning requiring close patient
monitoring, administration of prophylactic granulocyte-colony-
stimulating factors, and a low threshold for dose adjustments
[37]. Cabazitaxel also has black-box warnings for severe hyper-
sensitivity and is contraindicated in patients with hypersensitiv-
ity to polysorbate 80 formulation.
Minerocorticoid-related AEs, including ﬂuid retention (31% vs.
22%), hypertension (10% vs. 8%), and hypokalemia (17% vs. 8%),
were more frequently documented with abiraterone than with
placebo. These AEs can be managed with minerocorticoid recep-
tor antagonist [37]. Similar safety proﬁle was documented with
abiraterone in the chemotherapy-naive patient population [44].
Fatigue is the main AE observed with enzalutamide (all
grades, 34%; grade 3/4, 6%), followed by diarrhea (21%) and hot
ﬂashes (20%) [15]. Seizures (grade 3/4 in severity) have rarely been
associated with enzalutamide, occurring in 0.6% of the patients,
with some of the patients having confounding factors for seizure
development [15].
Grade 3/4 hypocalcemia and anemia occurred more com-
monly in the zoledronic acid arm than with placebo [66]. Also,
grade 3 (but not grade 4) serum creatinine elevations, mainly due
to the short infusion time, were seen more commonly with
zoledronic acid than with placebo [66]. Osteonecrosis of the jaw,
a rare but serious AE of bisphosphonates, typically occurs in
patients with poor dentition.
Denosumab was well tolerated in patients with bone metastases
and CRPC. The most common AEs with denosumab were anemia,
back pain, decreased appetite, nausea, fatigue, constipation, and
bone pain [39]. Hypocalcemia was more frequent (13%) with
denosumab than with zoledronic acid (6%) [39]. Osteonecrosis of
the jaw was also documented with this agent (2.3% with denosu-
mab and 1.3% with zoledronic acid). Unlike zoledronic acid, which
requires monitoring of renal function, denosumab does not impair
renal function and can be prescribed to patients with severe renal
impairment, but close monitoring of calcium levels is required.
The most common AEs (all grades) with radium-223 were
bone pain (50%), nausea (36%), anemia (31%), and diarrhea (25%).
Grade 3/4 AEs were infrequent, with bone pain (21%) and anemia
Table 4 – PROs of systemic and bone-targeted therapies from CRPC from pivotal phase 3 studies.
Trial Study arms Number of
patients
PRO End point Palliative outcomes Instruments Results P
Zoledronic acid [66] Zoledronic acid
(4 mg)
214 Secondary QOL assessment
(pain score,
analgesic score,
ECOG PS)
BPI-SF 0.58 (95% CI 0.29–0.87) 0.134
Zoledronic acid
(8/4 mg)
221 0.43 (95% CI 0.16–0.70) 0.026
(ZOMETA 039)
Placebo 208 0.88 (95% CI 0.61–1.15)
Modiﬁed Radiation
Therapy
Oncology Group
analgesic scale
Increased from baseline NS
ECOG PS Increased from baseline NS
FACT-G/Euro QOL
EQ-5D
questionnaire
Decreased from baseline NS
Docetaxel [13,28] Prednisone þ
mitoxantrone
337 Secondary Pain response PPI 22 0.01
Prednisone þ
docetaxel (q3w)
335 35 0.08
(TAX-327)
Prednisone þ
docetaxel (qw)
334 31 –
Secondary QOL assessment FACT-P 13 0.009
22 0.005
23 –
Docetaxel [29] Mitoxantrone s/p
docetaxel
67 Secondary Pain response PPI 29
Docetaxel (q3w)
s/p mitoxantrone
89 43 –
(TAX-327)
Docetaxel (qw) s/p
mitoxantrone
67 21
Secondary QOL assessment FACT-P 17
30
35 –
Abiraterone [38] Prednisone þ
abiraterone
797 Secondary Pain response
(interim)
BPI-SF 44 0.002
Prednisone þ
placebo
398 27
(COU-301)
Abiraterone [42] Secondary Fatigue BFI-SF (Fatigue
Intensity)
57 0.0001
40(COU-301)
BFI-SF (Fatigue
Interference)
55 0.0096
38
Abiraterone [43] Prednisone þ
abiraterone
546 Secondary Pain response
(long-term)
BPI-SF (Pain
Intensity)
45 0.0005
(COU-301) 29
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Table 4 – continued
Abiraterone [44] Secondary ECOG PS ECOG PS Time to ECOG PS
deterioration was
signiﬁcantly delayed by
abiraterone
0.0053
Prednisone þ
placebo
542 m (HR 0.82; 95% CI 0.71–0.94)
(COU-302)
Secondary Opiate use BPI-SF Time to opiate use (cancer-
related pain) (HR 0.69; 95%
CI0.57–0.83)
0.0001
Enzalutamide [15] Enzalutamide 800 Secondary QOL assessment FACT-P 43 o0.0001
Placebo 399 Secondary Pain response BPI-SF 18(AFFIRM)
Not yet reported NA
Cabazitaxel [37] Prednisone þ
cabazitaxel
378 Secondary Pain response PPI 9.2 0.63
(TROPIC)
Prednisone þ
mitoxantrone
377 7.7
Cabazitaxel [41] Prednisone þ
cabazitaxel
333 Secondary ECOG PS ECOG PS 79 (stable PS) –
(TROPIC)
Prednisone þ
mitoxantrone
324 78 (stable PS)
Secondary PPI improvement
rate
PPI 21 –
18
– Secondary PPI worsening rate PPI 32 –
32
Radium-223 [45] Radium-223 541 Secondary ECOG PS ECOG PS Time to ECOG PS
deterioration was
signiﬁcantly delayed by
radium-223
0.003
Placebo 268 (HR 0.62; 95% CI 0.46–0.85)
(ALSYMPCA)
QOL assessment FACT-P Not yet reported NA
BFI, Brief Fatigue Inventory; BPI-SF, Brief Pain Inventory-Short Form; CI, conﬁdence interval; ECOG, Eastern Cooperative Oncology Group; EQ-5D, EuroQol ﬁve-dimensional; EORTC, European
Organization for Research and Treatment of Cancer; FACT-P, Functional Assessment of Cancer Therapy-Prostate; FLIC, Functional Living Index-Cancer; HR, hazard ratio; IPDA, Impact of Pain
on Daily Activities; NA, not applicable; PDA, Problems in Daily Activities; PPI, Present Pain Intensity; PS, performance status; qw, every week; q3w, every 3 wk; QOL, quality of life; QOLM-P14,
Quality of Life Module-Prostate 14; SDS, Symptom Distress Scale; s/p, status post; SUF, sexual and urologic functioning.
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 7 2 – 8 9 0 887(13%). The lack of substantial myelosuppression with radium-223
contrasts with those in previous studies of β-emitting radio-
pharmaceuticals and may allow for concurrent administration
with traditional or hormonal therapies.
Detailed safety data from pivotal phase 3 studies for new
systemic and bone-targeted agents in CRPC are listed in Table 5.Discussion
A tremendous effort has been made in the last decade to better
our understanding of the biology of mCRPC. This has resulted in
the discovery of many new promising agents to treat this disease,
as identiﬁed by the results of our systematic review. Importantly,Table 5 – Tolerability of systemic and bone-targeted the
Drug name All grades (incidence ≥ 20%)
Chemotherapy
Docetaxel (TAX-
327) [13]
Anemia (67%), alopecia (65%), fatigue (53%),
neutropenia (41%), nausea (41%), infection
(32%), diarrhea (32%), nail changes (30%),
sensory neuropathy (30%), ﬂuid retention
(24%), and stomatitis/pharyngitis (20%)
N
Cabazitaxel
(TROPIC) [37]
Leukopenia (92%), neutropenia (88%), anemia
(81%), thrombocytopenia (43%), fatigue
(27%), and nausea (23%)
N
Immunotherapy
Sipuleucel-T
(IMPACT) [23]
Chills (54%), fatigue (39%), back pain (34%),
fever (31%), pyrexia (29%), nausea (28%),
arthralgia (21%), and citrate toxicity (20%)
B
Hormonal therapy
Abiraterone
acetate (COU
301) [38]
Fatigue (44%), ﬂuid retention/edema (31%),
back pain (30%), nausea (30%), arthralgia
(27%), constipation (26%), bone pain (25%),
anemia 23%), and vomiting (21%)
F
Abiraterone
acetate (COU
302) [44]
Fatigue (39%), ﬂuid retention (28%), and
hypertension (22%)
C
Enzalutamide
(AFFIRM) [15]
Fatigue (34%), diarrhea (21%), hot ﬂashes
(20%)
F
Bone-targeted therapy
Zoledronic acid
(ZOMETA 039)
[66]
Bone pain (51%), nausea (36%), constipation
(34%), fatigue (33%), anemia (27%), myalgia
(25%), vomiting (22%), weakness (21%),
anorexia (20%), and fever (20%)
A
Denosumab [39] Anemia (36%), back pain (32%), nausea (29%),
decreased appetite (28%), fatigue (27%),
constipation (25%), bone pain (25%),
asthenia (25%), arthralgia (21%), pain in
extremity (21%), and peripheral edema
(20%)
H
Radiopharmaceutical therapy
Radium-223
(ALSYMPCA)
[14]
Bone pain (50%), nausea (34.6%), anemia
(31%), and diarrhea (25%)
B
AE, adverse event; ALT, alkaline aminotransferase; AST, aspartase amin
 Cardiac disorders included ischemic heart disease, myocardial infarctio
cardiac failure, and possible arrhythmia-related tests, signs, and sympthe recent progress in the treatment of mCRPC highlights a global
paradigm shift away from the traditional classes of cytotoxic and
hormonal therapies toward a strategy that targets the tumor
microenvironment with novel targeted and immune therapies.
The beneﬁts of this strategy are supported by the FDA
approval of four novel agents that have been shown to prolong
survival in patients with mCRPC (sipuleucel-T, cabazitaxel, abir-
aterone, and enzalutamide). In addition, radium-223 has reported
survival improvements in the pivotal phase 3 trial, and the FDA
will be considering these positive data for a potential approval in
the near future.
Speciﬁc to CRPC with bone metastases, the FDA approval of
denosumab has offered another treatment option along with
zoledronic acid for this patient population. Last, radium-223 andrapies from CRPC from pivotal phase 3 studies.
Grades ≥3 (incidence ≥2%) Discontinuation
rate AE (%)
eutropenia (32%), infection (6%), anemia
(5%), fatigue (5%), nausea (3%), dyspnea
(3%), sensory neuropathy (2%), diarrhea
(2%), and vomiting (2%)
11
eutropenia (58%), leukopenia (42%), anemia
(5%), fatigue (3%), back pain (3%), asthenia
(2%), and bone pain (2%)
18
ack pain (4%) 1
atigue (o9%), anemia (7%), back pain (o7%),
bone pain (o6%), arthralgia (4%), cardiac
disorders (4%), liver function
abnormalities (o4%), hypokalemia (o4%),
nausea (o3%), vomiting (o3%), pain in arm
or leg (o3%), ﬂuid retention/edema (o3%),
asthenia (2%), urinary tract infection (2%),
and abdominal pain (2%)
19
ardiac disorders (6%), increased ALT (5%),
hypertension (4%), increased AST (3%),
hypokalemia (2%), and fatigue (2%)
7
atigue (6%) 8
nemia (5%), renal dysfunction (3% grade 3;
no grade 4), and hypocalcemia (2%)
18
ypocalcemia (5%) 17
one pain (21%), anemia (13%),
thrombocytopenia (6%), neutropenia (2%),
nausea (2%), diarrhea (2%), and vomiting
(2%)
17
otransferase.
n, supraventricular tachyarrhythmias, ventricular tachyarrhythmias,
toms.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 7 2 – 8 9 0888enzalutamide have a dual potential for not only improving OS but
also further expanding the availability of agents in patients with
bone metastases by delaying the development of SREs.
Concurrent with substantial excitement surrounding the
availability of the numerous therapeutic options with meaningful
survival beneﬁt for patients with CRPC come challenges for the
oncology community surrounding the rational use of these
agents (best sequencing and potential combination approaches).
Combinations of hormonal and/or targeted agents with cytotoxic
therapies are particularly attractive due to lack of overlapping
toxicities and potential for synergy based on differing mecha-
nisms of action. Both these treatment approaches will need to be
investigated in future clinical trials to make sure that patients
with mCRPC derive the optimal beneﬁt from these therapies.
Our systematic literature review was limited to a qualitative
description of the included randomized trials, limiting in-depth
comparison of the new systemic therapies. The majority of the
studies identiﬁed through our literature search did not have an
active comparator arm, thus not permitting direct comparison of
efﬁcacy, PROs, and safety of new systemic and bone-targeted
therapies. Speciﬁc to PROs, variability in the end points and
inconsistency in the use of instruments to measure them limit
our ability to clearly report their potential beneﬁts. Furthermore,
most studies were powered on the basis of the primary end point
of OS or PFS, diminishing the value of PRO results. To address this
limitation, future studies should consider the size of the study
population needed to obtain meaningful PRO data.
Last, our literature search reveals the scarcity and outdated
nature of the similar research in the existing literature. For
example, a systematic literature search performed by Mason
et al. [51] that investigated new therapies for CRPC encompassing
the 2000–2009 time frame found a limited number of published
phase 2 and 3 randomized clinical trials for second-line treatments
for mCRPC in docetaxel-pretreated patients, with no agent dem-
onstrating a survival beneﬁt. Because the ending date (2009) for
this systematic review was before the FDA approval of cabazitaxel
in 2010 (the ﬁrst agent with OS beneﬁt in the second-line setting),
it is not surprising that among 52 publications screened, only 3
trials were included for satraplatin, ixabepilone, and custirsen,
providing added value to our timely literature review [39]. Two of
these trials were included in our systematic literature review; the
ixabepilone trial was not captured, most likely because this agent
was not part of our search term strategy. A similar time frame
limitation (1988–2009) in the quickly changing therapeutic land-
scape of CRPC was at play in a systematic literature review of PROs
by Colloca et al. [49]. In contrast to our ﬁndings that reported pain
as the most common PRO, QOL was the most common PRO in the
Colloca investigation. Because our literature search focused on
evaluating newer targeted therapies with a potential for increased
antitumor activity in metastatic sites such as bones versus older
chemotherapeutic agents that historically have been less selective,
however, the pain assessment may be more relevant in the
current treatment landscape.Conclusions
This is an extraordinary period in the history of therapeutic
advances in mCRPC. The number of treatment options with
documented survival beneﬁt of about 4 months in this patient
population has increased over the last 2 years with the FDA
approvals of sipuleucel-T, cabazitaxel, abiraterone, and enzalu-
tamide, as shown by the results of our systematic literature
search. In addition, positive results have been reported for
radium-223, including OS improvements, and it may be added
to the therapeutic options of mCRPC in the foreseeable future.
Advancements have also been made in bone-targeted therapieswith the approval of denosumb after showing delay of bone
complications in patients with bone metastases. Reduction in
bone complications has also been documented with radium-223
and enzalutamide in addition to the OS improvement.
Despite this substantial progress in outcomes, as shown by
our results, PROs have been incorporated in many studies of
these new therapies, but they were analyzed as secondary end
points with delayed reporting of results. Most studies were
powered on the basis of the primary end point of OS or PFS,
and thus, the utility of PRO results has been limited; future
studies should consider the size of the study population needed
to obtain meaningful PRO data. In addition, efforts should con-
tinue to incorporate PROs through intelligent trial designs that
involve PROs in selected patient populations such as patients
with mCRPC.
Overall, these are exciting times for the treatment of mCRPC,
but it is now crucial that these new agents are appropriately
added to the treatment guidelines/pathways to maximize bene-
ﬁts for patients with mCRPC in light of their unique safety
proﬁles.
Sources of ﬁnancial support: Bayer HealthCare Pharmaceut-
icals provided funding for this study.
R E F E R E N C E S[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J
Clin 2013;63:11–30.
[2] Howlader N, Noone AM, Krapcho M, eds. SEER Cancer Statistics Review,
1975–2008. Bethesda, MD: National Cancer Institute, 2011. Available
from: http://seer.cancer.gov/csr/1975_2008/ based on November 2010
SEER data submission, posted to the SEER Web site, 2011 [Accessed
March 11, 2013].
[3] Goetz D. New options for the management of castration-resistant
prostate: a case perspective. J Natl Compr Canc Netw 2011;9(Suppl 3):
S13–24.
[4] Goktas S, Crawford D. Optimal hormone therapy for advanced prostatic
carcinoma. Semin Oncol 1999;26:162–73.
[5] National Comprehensive Cancer Network (NCCN) Practice Guidelines in
OncologyTM. Available from: http://www.nccn.org. [Accessed April 7,
2012].
[6] George D, Moul JW. Emerging treatment options for patients with
castration-resistant prostate cancer. Prostate 2012;72:338–49.
[7] Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral
orchiectomy with or without ﬂutamide for metastatic prostate cancer.
N Engl J Med 1998;339:1036–42.
[8] Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of
leuprolide with and without ﬂutamide in prostatic carcinoma. N Engl J
Med 1989;321:419–24.
[9] Higano CS, Crawford ED. New and emerging agents for the treatment
of castration-resistant prostate cancer. Urol Oncol 2011;29(Suppl 6):
S1–8.
[10] Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant prostate
cancer: from new pathophysiology to new treatment targets. Eur Urol
2009;56:594–605.
[11] Shelley M, Harrison C, Coles B, et al. Chemotherapy for hormone-
refractory prostate cancer. Cochrane Database Syst Rev 2006;18(4):CD
005247.
[12] Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and
estramustine compared with mitoxantrone and prednisone for
advance refractory prostate cancer. N Engl J Med 2004;351:1513–20.
[13] Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med 2004;351:1502–12.
[14] Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III,
double-blind, randomized, multinational study of radium-223 chloride
in castration-resistant prostate cancer (CPRC) patients with bone
metastases (ALSYMPCA). Presented at: American Society of Clinical
Oncology (ASCO). Chicago, IL, May 31-June 4, 2012.
[15] de Bono JS, Fizazi K, Saad F, et al. Phase 3 trial (AFFIRM) of
enzalutamide (MDV3100), an androgen receptor signaling inhibitor:
primary, secondary, and quality-of-life endpoint results. Presented at:
American Society of Clinical Oncology (ASCO). Chicago, IL, May 31-June
4, 2012.
[16] Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in
symptomatic, hormone-refractory prostate cancer: a randomised,
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 7 2 – 8 9 0 889multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8
(7):587–94.
[17] Fizazi KP, Beuzeboc J, Lumbroso V, et al. Phase II trial of consolidation
docetaxel and samarium-153 in patients with bone metastases from
castration-resistant prostate cancer. J Clin Oncol 2009;27(15):2429–35.
[18] Lipscomb J, Gotay CC, Snyder CE. Patient-reported outcomes in cancer:
a review of recent research and policy initiatives. CA Cancer J Clin
2007;57:278–300.
[19] Mottet N, Bellmunt J, Bolla M, et al. EUA guidelines on prostate cancer,
part II: treatment of advance, relapsing, and castration-resistant
prostate cancer. Eur Urol 2011;59:572–83.
[20] Di Lorenzo G, Buonerba C, Autorino R, et al. Castration-resistant
prostate cancer: current and emerging treatment strategies. Drugs
2010;70:983–1000.
[21] So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer.
Expert Rev Anticancer Ther 2006;9:1163–7.
[22] Provenges (sipuleucel-T) [package insert]. Seattle, WA: Dendreon
Corporation, June 2011.
[23] Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy
for castration-resistant prostate cancer. N Engl J Med 2010;363:411–22.
[24] Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase
III trial of immunologic therapy with sipuleucel-T (APC8015) in patients
with metastatic, asymptomatic hormone refractory prostate cancer. J
Clin Oncol 2006;24(19):3089–94.
[25] Mezynski JG, Attard A, Zivi D, et al. Evaluating the antitumour activity
of docetaxel following treatment with abiraterone acetate and steroids:
evidence for cross-resistance. Crit Rev Oncol Hematol 2011;78(Suppl):
S23–4.
[26] Bompas E, Italiano A, Ortholan C, et al. Docetaxel-based chemotherapy
in elderly patients (≥75 years) with castration resistant prostate cancer
(CRPC): a French national study of 175 patients. Abstract presented at:
ASCO Annual Meeting. Chicago, IL, May 30-June 3, 2008.
[27] Oudard S, Banu E, Medioni J, et al. What is the real impact of bone pain
on survival in patients with metastatic hormone-refractory prostate
cancer treated with docetaxel? BJU Int 2009;103:1641–6.
[28] Berthold DR, Pond GR, Roessner M, et al. Treatment of hormone-
refractory prostate cancer with docetaxel or mitoxantrone:
relationships between prostate-speciﬁc antigen, pain, and quality of
life response and survival in the TAX-327 study. Clin Cancer Res
2008;14:2763–7.
[29] Berthold DR, Pond GR, de Wit R, et al. Survival and PSA response of
patients in the TAX 327 study who crossed over to receive docetaxel
after mitoxantrone or vice versa. Ann Oncol 2008;19:1749–53.
[30] Saad F, Perez J, Cook R, et al. Evaluation of prostate-speciﬁc antigen
kinetics during zoledronic acid therapy for bone metastases in patients
with castration-resistant prostate cancer. Abstract presented at: AUA
Annual Meeting. Washington, DC, May 14–19, 2011.
[31] Nilsson S, Parker C, Biggin C, et al. Clinical experience and radiation
safety of the ﬁrst-in-class alpha-pharmaceutical, Alpharadin™
(radium-223), in patients with castration-resistant prostate cancer
(CRPC) and bone metastases. Poster presented at: American Society for
Radiation Oncology (ASTRO). San Diego, CA, October 21-November 4,
2010.
[32] Michaelson MD, Kaufman DS, Kantoff P, Smith MR. Randomized phase
II study of atrasentan alone or in combination with zoledronic acid in
men with metastatic prostate cancer. Cancer 2006;107:530–5.
[33] Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel
and prednisone with or without OGX-011 in patients with metastatic
castration-resistant prostate cancer. J Clin Oncol 2010;28:4247–54.
[34] Parker C, O’Bryan-Tear CG, Bolstad B, et al. Alkaline phosphatase (ALP)
normalization and overall survival in patients with bone metastases
from castration-resistant prostate cancer (CRPC) treated with radium-
223. Poster presented at: American Society of Clinical Oncology (ASCO)
Genitourinary Cancers Symposium. San Francisco, CA, March 5–7, 2010.
[35] Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind,
phase III study of prednisone and either satraplatin or placebo in
patients with castrate-refractory prostate cancer progressing after prior
chemotherapy: the SPARC trial. J Clin Oncol 2009;32:5431–8.
[36] Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind,
placebo-controlled phase III trial comparing docetaxel, prednisone, and
placebo with docetaxel, prednisone, and bevacizumab in men with
metastatic castration-resistant prostate cancer (mCRPC): survival
results of CALGB 90401. Abstract presented at: ASCO Annual Meeting.
Chicago, IL, June 4–8, 2010.
[37] de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or
mitoxantrone for metastatic castration-resistant prostate cancer
progressing after docetaxel treatment: a randomized open-label trial.
Lancet 2010;376:1147–54.
[38] de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased
survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.
[39] Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid
for treatment of bone metastases in men with castration-resistantprostate cancer: a randomised, double-blind study. Lancet
2011;377:813–22.
[40] Meulenbeld HJ, van Werkhoven ED, Coenen JLLM, et al. Randomized
phase III study of docetaxel with or without risedronate in patients
with bone metastases from castration-resistant prostate cancer (CRPC):
the Netherlands Prostate Study (NePro). Abstract presented at: ASCO
Annual Meeting. Chicago, IL, June 3–7, 2011.
[41] Tombal B, Oudard S, Ozguroglu M, et al. Clinical beneﬁt of cabazitaxel
plus prednisone in the TROPIC trial in men with metastatic castration
resistant prostate cancer (mCRPC) who progressed after docetaxel-
based treatment. Eur Urol Suppl 2011;10:335–6.
[42] Sternberg CN, Scher HI, Molina A, et al. Fatigue improvement/reduction
with abiraterone acetate in patients with metastatic castration-
resistant prostate cancer post-docetaxel: results from the COU-AA-301
phase 3 study. Poster presented at: European Multidisciplinary Cancer
Congress (EMCC). Stockholm, Sweden, September 23–27, 2011.
[43] Basch EM, de Bono JS, Scher HI, et al. Pain control and delay in time to
skeletal-related events (SREs) in patients with metastatic castration-
resistant prostate cancer (mCPRC) treated with abiraterone acetate
(AA): long-term follow-up. J Clin Oncol 2012(Suppl. 5): abstract 183.
[44] Ryan CJ, de Bono JS, Molina A, et al. Interim analysis (IA) results of COU-
AA-302, a randomized, phase 3 study of abiraterone acetate (AA) in
chemotherapy-naïve patients (pts) with metastatic castration-resistant
prostate cancer (mCRPC). Presentation presented at: American Society
of Clinical Oncology (ASCO). Chicago, IL, May 31-June 4, 2012.
[45] Sartor AO, Heinrich D, O’Sullivan JM, et al. Radium-223 chloride (Ra-
223) impact on skeletal related events (SREs) and ECOG performance
status (PS) in patients with castration-resistant prostate cancer (CRPC)
with bone metastases: interim results of a phase III trial (ALSYMPCA).
J Clin Oncol 2012(Suppl):: abstract 4551.
[46] Moser L, Schubert T, Hinkelbein W. Hormone-refractory and metastatic
prostate cancer—palliative radiotherapy. Front Radiat Ther Oncol
2008;41:117–25.
[47] Liepe K. Alpharadin, a 223Ra-based (alpha)-particle-emitting
pharmaceutical for the treatment of bone metastases in patients with
cancer. Curr Opin Investig Drugs 2009;12(10):1346–58.
[48] Vogiatzi P, Cassone M, Claudio L, et al. Targeted therapy for advanced
prostate cancer: looking through new lenses. Drug News Perspect
2009;22:593–601.
[49] Colloca G, Venturino A, Checcaglini F. Patient-reported outcomes after
cytotoxic chemotherapy in metastatic castration-resistant prostate
cancer: a systematic review. Cancer Treat Rev 2010;36:501–6.
[50] Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches
targeting bone complications in prostate cancer. Clin Genitourin
Cancer 2010;8:29–36.
[51] Mason M, Freemantle N, Parnaby A, et al. No conclusive evidence from
randomized controlled trials (RCTs) for improved survival with second-
line treatment options, in patients with metastatic hormone-refractory
prostate cancer (mHRPC) previously treated with docetaxel. Value
Health 2010;13:A254.
[52] Santini D, Galluzzo S, Zoccoli A, et al. New molecular targets in bone
metastases. Cancer Treat Rev 2010;36(Suppl. 3):S6–10.
[53] Bourgeois DJ, Kraus S, Maaloof BN, et al. Radiation for bone metastases.
Curr Opin Support Palliat Care 2011;5:227–32.
[54] Yap TA, Zivi A, Omlin A, et al. The changing therapeutic landscape of
castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:597–610.
[55] Attard G, Belldegrun AS, de Bono JS. Selective blockage of androgenic
steroid synthesis by novel lyase inhibitors as a therapeutic strategy for
treating metastatic prostate cancer. BJU Int 2005;96:1241–6.
[56] Osoba D, Tannock IF, Ernst DS, et al. Health-related quality of life in
men with metastatic prostate cancer treated with prednisone alone or
mitoxantrone and prednisone. J Clin Oncol 1999;17:1654–63.
[57] Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with
mitoxantrone plus prednisone or prednisone alone for symptomatic
hormone-resistant prostate cancer: a Canadian randomized trial with
palliative end points. J Clin Oncol 1996;14:1756–64.
[58] Taxoteres (docetaxel) [package insert]. Bridgewater, NJ: Sanoﬁ-Aventis,
U.S. LLC, May 2010.
[59] Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer: updated
survival in the TAX 327 study. J Clin Oncol 2008;26:242–5.
[60] Aller AW, Kraus LA, Bissery M-C. In vitro activity of TXD258 in
chemotherapeutic resistant tumor cell lines [abstract 1923]. Proc Am
Assoc Cancer Res 2000;41:303.
[61] Bissery M-C, Bouchard H, Riou JF, et al. Preclinical evaluation of
TXD258, a new taxoid [abstract 1364]. Proc Am Assoc Cancer Res
2000;41:214.
[62] Singer EA, Srinivasan R. Intravenous therapies for castration-resistant
prostate cancer: toxicities and adverse events. Urol Oncol 2012;30
(Suppl. 4):S15–9.
[63] Jevtanas (cabazitaxel) [package insert]. Bridgewater, NJ: Sanoﬁ-Aventis,
U.S. LLC, June 2010.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 7 2 – 8 9 0890[64] Zytigas (abiraterone acetate) [package insert]. Horsham, PA: Centocor
Ortho Biotech, Inc., April 2011.
[65] Zometas (zoledronic acid) [package insert]. East Hanover, PA: Novartis
Pharmaceuticals Corporation, June 2011.
[66] Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled
trial of zoledronic acid in patients with hormone-refractory metastatic
prostatic carcinoma. J Natl Cancer Inst 2002;94:1458–68.
[67] Dayyani F, Gallick GE, Logothetis CJ, et al. Novel therapies for metastatic
castrate-resistant prostate cancer. J Natl Cancer Inst 2011;103:1665–75.
[68] Xgevas (denosumab) [package insert]. Thousand Oak, CA: Amgen, Inc.,
November 2010.
[69] Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study
of denosumab vs. zoledronic acid in the treatment of bone metastases
in patients with advanced cancer (excluding breast
and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125–32.
[70] Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with
zoledronic acid for the treatment of bone metastases in patients with
advanced breast cancer: a randomized, double-blind study. J Clin Oncol
2010;28:5132–9.
[71] Melzack R. The McGill Pain Questionnaire: major properties and scoring
methods. Pain 1975;1:277–99.[72] Gater A, Abetz-Webb L, Battersby C, et al. Pain in castration-resistant
prostate cancer with bone metastases: a qualitative study. Health Qual
Life Outcomes 2011;9:1–11.
[73] Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain
Inventory. Ann Acad Med Singa 1994;23(2):129–38.
[74] Farrar JT, Young JP, LaMoreaux L, et al. Clinical importance of changes
in chronic pain intensity measured on an 11-point numerical pain
rating scale. Pain 2001;94:149–58.
[75] Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with
prostate cancer using the functional assessment of cancer therapy-
prostate instrument. Urology 1997;50:920–8.
[76] Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer
Therapy scale: development and validation of the general measure.
J Clin Oncol 1993;11:570–9.
[77] Cella D, Nichol MB, Eton D, et al. Estimating clinically meaningful
changes for the functional assessment of cancer therapy—prostate:
results from a clinical trial of patients with metastatic hormone-
refractory prostate cancer. Value Health 2009;12:124–9.
[78] Sternberg CN, Molina A, North S, et al. Effect of abiraterone acetate on
fatigue in patients with metastatic castration-resistant prostate cancer
after docetaxel chemotherapy. Ann Oncol 2013;4:1017–25.
